Prana Biotechnology Presents at the 9th International Conference on Alzheimer's Disease

Prana Biotechnology Presents at the 9th International Conference
on Alzheimer's Disease
Co-founding scientist to discuss new data on the interaction of cholesterol
with beta-amyloid and brain metals 


PHILADELPHIA, July 19  /PRNewswire-FirstCall/ -- Dr. Ashley Bush, chief
scientific consultant and co-founder of Prana Biotechnology Limited (NASDAQ:
PRAN)(ASX:PBT) is scheduled to present a lecture tonight at the 9th
International Conference on Alzheimer's Disease and Related Disorders  (ICAD),
a specialist international symposium in Philadelphia at the Pennsylvania
Convention Center, Ballroom A/B. The event will commence at 5:30 PM.

Dr. Bush intends to present a lecture entitled "Clioquinol and the Metal-
Protein Attenuating Compounds (MPACs*) in the treatment of Alzheimer's disease"
at a session devoted to the development of therapeutic strategies. Based on the
hypothesis that beta amyloid is a key player in the onset and progression of
Alzheimer's disease, Prana maintains that it is the inappropriate interaction
of beta amyloid with brain metals copper and zinc that leads to the progression
associated with the disease.  As part of his remarks, Dr. Bush intends to
discuss how clioquinol detects amyloid pathology in brain tissue and how the
drug arrives at the appropriate biochemical target in living transgenic mice
and in post-mortem tissue from patients with Alzheimer's disease.

Dr. Bush and his co-workers at the University of Melbourne and Massachusetts
General Hospital have developed this theory over 15 years of research. For much
of this time, the research community has been sceptical toward what was a major
departure from the more favoured theories. Invitations to present the MPAC
approach at premier conferences such as ICAD demonstrate the increasing support
for Prana's technology in the Alzheimer's community.

Co-founding Scientist of Prana, Dr. Rudolph E. Tanzi, Professor of Neurology at
Harvard Medical School said, "This conference is regarded as an important
event, not only for scientists and medical practitioners in the industry, but
also for the millions of patients worldwide who have Alzheimer's, This
invitation to speak to international peers about the scientific basis for
Prana's MPAC technology is an indication that our theories have achieved
considerable acceptance."

Also at ICAD, on Wednesday July 21, Dr. Bush is scheduled to give an invited
lecture that will review the basic neuroscience describing the involvement of
brain copper and zinc in Alzheimer pathology. New data is expected to be
presented on the interaction of cholesterol with beta-amyloid and brain metals,
which may play a key role in the sequence of events that leads to dementia. The
possibility that beta-amyloid participates in the functional regulation of
copper levels in health will be discussed.

(*MPACs, or Metal-Protein Attenuating Compounds are compounds that bind metals
to prevent their interactions with proteins.)

International Conference on Alzheimer's Disease (ICAD)

The ICAD is the world's leading forum on dementia research, and provides the
opportunity for more than 5,000 attending researchers to share knowledge and
develop creative new approaches to increasing the understanding of Alzheimer's.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000.
Researchers at prominent international institutions including the University of
Melbourne and Massachusetts General Hospital at Harvard Medical School
discovered Prana's technology.

This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the
Company expressly disclaims any obligation to provide public updates, revisions
or amendments to any forward-looking statements made herein to reflect changes
in the Company's expectations or future events.

For further information, please visit our web site at http://www.pranabio.com/.


DATASOURCE: Prana Biotechnology Limited



CONTACT:  Company - Geoffrey Kempler of Prana Biotechnology Ltd.,

[phone]; or Media - Ivette Almeida, [phone], ext. 209, or

Investor - Rachel Levine, both of The Anne McBride Company, [phone],

ext. 207



Web site:  http://www.pranabio.com/ 

Copyright